Bringing the very best science and medicine to our best equine friends
Investor

KindredBio Announces Pricing of Public Offering

SAN FRANCISCO, July 12, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $7.50 per share, for a total offering amount of $22.5 million before deducting underwriting discounts and commissions and estimated offering expenses payable by KindredBio. KindredBio has granted to the underwriters a 30-day option to purchase up to an additional 450,000 shares of its common stock. All of the shares are being offered by KindredBio. …

Continue Reading

KindredBio Announces Proposed Public Offering of Common Stock

SAN FRANCISCO, California. (July 11, 2017) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced a proposed public offering of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc., is acting as sole book-running manager and Aegis Capital Corp. is acting as the lead manager. KindredBio intends …

Continue Reading

Kindred Biosciences Announces Acquisition of Kansas Manufacturing Plant and Execution of Commercial Manufacturing Agreement for Zimeta

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Monday, June 26, 2017 San Francisco, CA (June 26, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has acquired a manufacturing facility in Elwood, Kansas. The purchase of this property, formerly owned by Boehringer Ingelheim and by Strategic Veterinary Pharmaceuticals, Inc., includes approximately 8 acres of land and two buildings encompassing approximately 180,000 square feet with clean rooms, utility, equipment, and related quality documentation suitable for small molecule …

Continue Reading

Kindred Biosciences Added to the Russell 2000 Index

San Francisco, June 15, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will join the US small-cap Russell 2000® Index, effective after the US market closes on June 23, according to a preliminary list of additions and the market capitalization cutoff posted June 14 as part of the 2017 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. The Company will also be automatically added to the appropriate …

Continue Reading

Kindred Biosciences to Present Data from Six Studies at the 2017 American College of Veterinary Internal Medicine Conference

San Francisco, CA (May 30, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will be presenting data from six studies at the 2017 American College of Veterinary Internal Medicine (ACVIM) conference in National Harbor, MD, held June 8-10, 2017.  The Company will be sharing effectiveness and safety data from its Mirataz™ (mirtazapine transdermal ointment) and Zimeta™ (dipyrone injection) development programs and sponsoring scientific sessions. In addition, KindredBio will be sponsoring five Scientific Sessions at the conference. “We are proud that all six of the abstracts we …

Continue Reading

Kindred Biosciences to Present at 7th Annual LD Micro Invitational

San Francisco, CA (May 24, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and COO, will be presenting and hosting one-on-one investor meetings at the 7thAnnual LD Micro Invitational in Los Angeles, CA on Tuesday, June 6, 2017 at 1:30 PM PST. The conference will be held at the Luxe Sunset Bel Air Hotel. Following the presentation, the slide deck will be available for 30 days on the Company’s website: https://kindredbio.com/investor-relations/events. About Kindred Biosciences Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and …

Continue Reading

Kindred Biosciences Announces First Quarter 2017 Financial Results

San Francisco, CA (May 3, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2017 and provided updates on its programs. “The first quarter of 2017 has been extremely successful for KindredBio. We continue to expect approval of Mirataz and Zimeta IV by second half of 2017, if the FDA review continues to proceed well. We have been receiving very positive feedback from key opinion leaders and other veterinarians about the product profiles of the products, and look forward to …

Continue Reading